Physician profile
Jerilyn Stewart
NPI 1780788042
$2,586.79
in general payments reported to CMS, 2019-2025
29 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $639 · 2023: $637 · 2024: $559 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.34 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $273.98 | 2021-2025 | |
| Lilly USA, LLC | $201.02 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $186.26 | 2021-2024 | Gardasil, Capvaxive, M-M-R II |
| Glaxosmithkline, LLC. | $156.14 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Ironshore Pharmaceuticals INC. | $147.40 | 2022-2023 | Jornay Pm |
| Abbvie INC. | $143.86 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $130.11 | 2022 | |
| Amgen INC. | $110.21 | 2023-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $95.89 | 2021-2023 | Trintellix |
| Abbott Laboratories | $91.29 | 2023 | Mitraclip |
| Novo Nordisk INC | $81.97 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.52 | 2021-2023 | Jardiance, Synjardy |
| Agile Therapeutics, INC. | $65.49 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $63.73 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $46.98 | 2023-2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $42.76 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $38.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $24.85 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $24.63 | 2024 | Thinprep 2000 Processor |
| Corcept Therapeutics | $20.64 | 2023 | Korlym |
| Vertex Pharmaceuticals Incorporated | $19.95 | 2024 | |
| Scilex Pharmaceuticals INC. | $19.74 | 2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.75 | 2024 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $15.27 | 2024 | Crysvita |
| Ironwood Pharmaceuticals, INC | $14.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $13.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerilyn Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.